Skingevity names new Chief Medical Officer to drive clinical excellence

Skingevity, a medical clinic operator focused on German-speaking countries, has appointed Dr. Simon Eccleston as its new Chief Medical Officer. The company, headquartered in London, continues to expand its leadership team as part of a broader UK-first growth strategy.

Eccleston will take on a key role in standardising practices and supporting clinical teams across the group.

Skingevity currently runs clinics mainly in Germany and Austria, though the exact number of locations worldwide remains undisclosed. The company's leadership now includes two co-CEOs: Agnolio, who serves as chief operating officer, and Ghio, who also holds the CFO position.

Agnolio previously worked as a principal at The Boston Consulting Group, while Ghio came from a background as an executive director at Goldman Sachs. Their combined experience guides Skingevity's expansion plans.

Eccleston's appointment aims to strengthen governance and education within the clinics. His responsibilities will include shaping shared standards for professional development and empowering local clinical leaders. The move reflects Skingevity's push for consistency as it grows internationally.

With Eccleston in place, Skingevity plans to refine its medical governance and training frameworks. The company's leadership changes come as it balances a UK-first approach with wider ambitions in Europe. Further details on clinic numbers and expansion timelines have not yet been made public.